Thu06202019

Robins Global News & Noticias



  • Shipping Advice
    Shipping Advice
  • Featured Guest Post
    Featured Guest Post
  • Featured Guest Post
    Featured Guest Post
  • Featured Guest Post
    Featured Guest Post
  • Trump Pence News
    Trump Pence News
  • Weather Alerts
    Weather Alerts

RobinsPost News Network

+ Larger Font | + Smaller Font

Globe NewsWire News Distribution Service

Press Release: Sorrento Therapeutics Expands Resiniferatoxin (RTX) Clinical Development Program to Life-Threatening Cardiovascular Diseases With Completion of Major Animal Toxicology Study


SAN DIEGO, April 15, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced that its Neuro-Therapeutics unit is pursuing clinical development of resiniferatoxin (RTX) for multiple life-threatening cardiovascular disorders, including IND enabling toxicology and proof-of-principle animal studies.
Cardiovascular diseases1 are the most common cause of death and disability globally and the approximate annual impact in the US includes over:9 million myocardial infarctions8 million people with peripheral artery disease 6 million people diagnosed with Chronic/Congestive Heart Failure (CHF)600,000 people who die of cardiovascular disease each year (1 in every 4 deaths)Pain, diminished quality of life and/or diminished patient life expectancy are associated with advance stages for all of these diseases.RTX has potential clinical benefits derived from its ability to modulate neurogenic inflammation and afferent nerve signaling commonly associated with chronic degenerative conditions. RTX specifically ablates sensory nerves that express the TRPV1 receptor.  These receptors are present in peripheral sensory neurons responsible for the sensation of pain, inflammation, and detection of high heat thresholds. TRPV1 is also found in central sensory ganglia and appear to play a role in integrating inflammatory signals to the brain.  At pharmacological doses of RTX, proprioceptive and motor neurons are not affected. Animal model data generated by academic institutions in the past years support the potential use of RTX in a variety of cardiovascular disorders. Published data key conclusions:Compared to control, RTX administered to the surface of the heart (epicardium) reduced cardiac and renal sympathetic nerve activity in animals who had a myocardial infarction (MI) with resulting chronic heart failure (CHF).  In addition, RTX treatment decreased cardiac fibrosis (remodeling), diastolic dysfunction (Wang et al. Hypertension 2014; Wang et al. J. Physiol 2017) and inflammation.Rats with CHF who have RTX induced ablation of the TRPV1 sensory thoracic and epicardial afferent nerves survived longer than control treated animals.Thoracic epidural RTX administration in spontaneously hypertensive rats reduced blood pressure or prevented the development of ...


Posted: 2019-04-15 08:00:00

Get Full News Story On GlobeNewsWire Press Release Service


Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.


Print Friendly and PDF Share Embed


Related News Stories From The Web And More

Related Bing News

Press Release: Sorrento Therapeutics Expands Resiniferatoxin (RTX) Clinical Development Program to Life-Threatening Cardiovascular Diseases With Completion of Major Animal Toxicology Study | Globe NewsWire News Distribution Service | RobinsPost News Network - Newscast

FDA Approves BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Combination for Patients with Advanced Renal Cell Carcinoma

Tue, 14 May 2019 16:50:00 GMT

Withhold BAVENCIO for moderate (Grade 2) and permanently discontinue for severe (Grade 3), life-threatening (Grade 4), or recurrent ... BAVENCIO in combination with INLYTA can cause major adverse ...

FDA Approves Bavencio Plus Inlyta Combination for Patients with Advanced Renal Cell Carcinoma

Mon, 13 May 2019 17:00:00 GMT

Withhold BAVENCIO for moderate (Grade 2) and permanently discontinue for severe (Grade 3), life-threatening (Grade 4), or recurrent ... BAVENCIO in combination with INLYTA can cause major adverse ...

Sanofi: FDA approves Praluent® (alirocumab) to prevent heart attack, stroke and unstable angina requiring hospitalization

Fri, 26 Apr 2019 16:25:00 GMT

"Praluent has already helped many adults lower their LDL-C levels, and this new indication provides an opportunity to help appropriate patients by reducing the risk of serious, life-threatening ... ...

In-Vitro Diagnostics Market 2023 Growth Insights, Size Expansion, Share Valuation, Industry News Update – Research Report by MRFR

Sun, 07 Apr 2019 20:03:00 GMT

The growth of the Global In-Vitro Diagnostics Market is stemmed from the rise in the prevalence of chronic diseases on a global scale. Diseases such as tuberculosis, diabetes, cancer, and ...

Palatin Technologies, Inc. (PTN) CEO Carl Spana on Q2 2019 Results - Earnings Call Transcript

Tue, 12 Feb 2019 11:13:00 GMT

Our PL-5028 is a dual natural peptide A receptor C agonist for use in cardiovascular and fibrotic diseases; including reduction of ... is doing its job and being careful. There is a ...

Related Bing Web Search

Sorrento Therapeutics Expands Resiniferatoxin (RTX ...

(Sun, 16 Jun 2019 06:52:00 GMT)

Sorrento Therapeutics Expands Resiniferatoxin (RTX) Clinical Development Program to Life-Threatening Cardiovascular Diseases With Completion of Major Animal Toxicology Study. Apr 15, 2019 at 4:00 AM EDT. ... (RTX) for multiple life-threatening cardiovascular disorders, ...

Sorrento Therapeutics Expands Resiniferatoxin (RTX ...

(Sun, 16 Jun 2019 13:11:00 GMT)

Sorrento Therapeutics Expands Resiniferatoxin (RTX) Clinical Development Program to Life-Threatening Cardiovascular Diseases With Completion of Major Animal Toxicology Study

Sorrento Therapeutics : Expands Resiniferatoxin Clinical ...

(Thu, 30 May 2019 19:08:00 GMT)

SAN DIEGO - Sorrento Therapeutics, Inc. (NASDAQ: SRNE, 'Sorrento'), announced that its Neuro-Therapeutics unit is pursuing clinical development of resiniferatoxin (RTX) for multiple life-threatening cardiovascular disorders, including IND enabling toxicology and proof-of-principle animal studies.. Cardiovascular diseases1 are the most common cause of death and disability globally and the ...

Sorrento Therapeutics Expands Resiniferatoxin (RTX ...

(Tue, 21 May 2019 21:49:00 GMT)

Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”), announced that its Neuro-Therapeutics unit is pursuing clinical development of resiniferatoxin (RTX) for multiple life-threatening cardiovascular disorders, including IND enabling toxicology and proof-of-principle animal studies. Cardiovascular diseases1 are the most

Sorrento Therapeutics Expands Resiniferatoxin (RTX ...

(Mon, 17 Jun 2019 01:57:00 GMT)

Indices Major Stock Indices ... Clinical Development Program to Life-Threatening Cardiovascular Diseases With Completion of Major Animal Toxicology Study ... for multiple life-threatening ...

Sorrento Therapeutics Expands Resiniferatoxin (RTX ...

(Thu, 06 Jun 2019 19:06:00 GMT)

Cloud Computing Magazine Click here to read latest issue Subscribe for FREE - Click Here IoT EVOLUTION MAGAZINE Click here to read latest issue Subscribe for FREE - Click Here

Sorrento Therapeutics Inc. (via Public) / Sorrento ...

(Tue, 11 Jun 2019 23:32:00 GMT)

Sorrento Therapeutics Expands Resiniferatoxin (RTX) Clinical Development Program to Life-Threatening Cardiovascular Diseases With Completion of Major Animal Toxicology Study. SAN DIEGO, April 15, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, 'Sorrento'), announced that its Neuro-Therapeutics unit is pursuing clinical ...

Sorrento Therapeutics Expands Resiniferatoxin (RTX ...

(Sun, 09 Jun 2019 08:47:00 GMT)

Visit the post for more. Sorrento Therapeutics Expands Resiniferatoxin (RTX) Clinical Development Program to Life-Threatening Cardiovascular Diseases With Completion of Major Animal Toxicology Study

Sorrento Therapeutics Expands Resiniferatoxin (RTX ...

(Wed, 12 Jun 2019 13:01:00 GMT)

Sorrento Therapeutics Expands Resiniferatoxin (RTX) Clinical Development Program to Life-Threatening Cardiovascular Diseases With Completion of Major Animal Toxicology Study. ... for multiple life-threatening cardiovascular disorders, including IND enabling toxicology and proof-of-principle animal studies. ... We have just completed a major ...

Related News Story Videos From Youtube

Life Threatening Hypothermia Emergency


Related Videos On: Life Threatening Hypothermia Emergency


Oral Health and Life-Threatening Diseases


Related Videos On: Oral Health and Life-Threatening Diseases


Red Blood Cell Life Cycle and Disorders, Animation


Related Videos On: Red Blood Cell Life Cycle and Disorders, Animation


Clinical case study AGE Reader - Cardiovascular risk in diabetes


Related Videos On: Clinical case study AGE Reader - Cardiovascular risk in diabetes


Circulatory Shock | Types and Causes


Related Videos On: Circulatory Shock | Types and Causes






Blow Us A Whistle

Comments (Whistles) Designed By Disqus




Company Information

Official Content Providers











PRIVACY POLICY

We recommend Firefox 3 (and above), Edge, and Chrome for dynamic performance.
© 2008-2019 RobinsPost (The Bird's Eye View Company) All rights are reserved.
RobinsPost provides links to news sites based on their RSS feeds.
All trademarks, copyrights, videos, photos and logos are owned by news sources.
News stories, videos and live streams are from trusted sources:
Bing News, Google News, Faroo News, NewsApi.org and YouTube Search Results.
ROBINSPOST Is Proudly Made In America.
Where Quality, Safety and Service Comes First.